Article
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
Blood - 2 Nov 2023
Acosta-Medina Aldo A, Kemps Paul G, Zondag Timo C E, Abeykoon Jithma P, Forma-Borst Jelske, Steenwijk Eline C, Feijen Elizabeth A M, Teepen Jop C, Bennani N Nora, Schram Susan M, Shah Mithun V, Davidge-Pitts Caroline, Koster Matthew J, Ryu Jay H, Vassallo Robert, Tobin W Oliver, Young Jason R, Dasari Surendra, Rech Karen, Ravindran Aishwarya, Cleven Arjen H G, Verdijk Robert M, van Noesel Carel J M, Balgobind Brian V, Bouma Gerrit Joan, Saeed Peerooz, Bramer Jos A M, de Groen Ruben A L, Vermaat Joost S P, van de Sande Michiel A J, Smit Egbert F, Langerak Anton W, van Wezel Tom, Tonino Sanne H, van den Bos Cor, van Laar Jan A M, Go Ronald S, Goyal Gaurav, van Halteren Astrid G S
Abstract excerpt
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clon...
Topics
- Humans
- Adult
- Neoplasms, Second Primary
- Proto-Oncogene Proteins B-raf
- Retrospective Studies
- Incidence
- Histiocytosis, Langerhans-Cell